Lunch ON 1mg Tablet contains Repaglinide 1mg, an oral antihyperglycemic agent used primarily for the management of type 2 diabetes mellitus. Repaglinide belongs to the meglitinide class of drugs, which act by stimulating pancreatic beta cells to release insulin, thereby reducing postprandial blood glucose levels. This rapid-acting insulin secretagogue is particularly effective in controlling blood sugar spikes after meals. Lunch ON 1mg Tablet is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes when metformin alone is insufficient or contraindicated. The medication is typically administered shortly before meals to optimize its efficacy in regulating post-meal glucose excursions. Common side effects may include hypoglycemia, headache, and gastrointestinal disturbances such as nausea. Caution is advised in patients with hepatic or renal impairment, and dose adjustments may be necessary. Repaglinide should be used with careful monitoring to avoid hypoglycemia, especially when combined with other antidiabetic agents. Patients are advised to adhere strictly to prescribed dosing schedules and maintain regular blood glucose monitoring to ensure optimal therapeutic outcomes. Lunch ON 1mg Tablet offers a targeted approach to postprandial hyperglycemia, contributing to overall glycemic management in type 2 diabetes.